Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.

Vicki L. Fisher, Yvonne J. Barnes, Suzanne L. Nuss

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

PURPOSE/OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. DATA SYNTHESIS: Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects. CONCLUSIONS: IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. IMPLICATIONS FOR NURSING: An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.

Original languageEnglish (US)
Pages (from-to)E36-43
JournalOncology nursing forum
Volume33
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Busulfan
Hematopoietic Stem Cell Transplantation
Pharmacokinetics
Investigational Drugs
Product Labeling
Drug Monitoring
Poisons
MEDLINE
Disease Progression
Therapeutics

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

Pretransplant conditioning in adults and children : dose assurance with intravenous busulfan. / Fisher, Vicki L.; Barnes, Yvonne J.; Nuss, Suzanne L.

In: Oncology nursing forum, Vol. 33, No. 2, 03.2006, p. E36-43.

Research output: Contribution to journalReview article

@article{92a12d2beb6b4fb5a66e4b4628e45477,
title = "Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.",
abstract = "PURPOSE/OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. DATA SYNTHESIS: Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects. CONCLUSIONS: IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. IMPLICATIONS FOR NURSING: An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.",
author = "Fisher, {Vicki L.} and Barnes, {Yvonne J.} and Nuss, {Suzanne L.}",
year = "2006",
month = "3",
doi = "10.1188/06.ONF.E36-E43",
language = "English (US)",
volume = "33",
pages = "E36--43",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "2",

}

TY - JOUR

T1 - Pretransplant conditioning in adults and children

T2 - dose assurance with intravenous busulfan.

AU - Fisher, Vicki L.

AU - Barnes, Yvonne J.

AU - Nuss, Suzanne L.

PY - 2006/3

Y1 - 2006/3

N2 - PURPOSE/OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. DATA SYNTHESIS: Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects. CONCLUSIONS: IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. IMPLICATIONS FOR NURSING: An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.

AB - PURPOSE/OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. DATA SYNTHESIS: Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects. CONCLUSIONS: IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. IMPLICATIONS FOR NURSING: An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.

UR - http://www.scopus.com/inward/record.url?scp=33646837336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646837336&partnerID=8YFLogxK

U2 - 10.1188/06.ONF.E36-E43

DO - 10.1188/06.ONF.E36-E43

M3 - Review article

C2 - 16518436

AN - SCOPUS:33646837336

VL - 33

SP - E36-43

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 2

ER -